论文部分内容阅读
目的:观察参芪扶正注射液联合肝动脉化疗栓塞(TACE)治疗原发性肝癌的临床疗效及不良反应。方法:选取河北省民政总医院2013年11月至2015年5月收治的94例肝癌患者随机分为治疗组51例和对照组43例,均进行肝动脉化疗栓塞治疗,治疗组加用参芪扶正注射液,观察两组的生存期、生化指标变化、不良反应、临床疗效及生活质量改善情况。结果:治疗组总有效率为76.47%,高于对照组的67.44%,治疗组临床疗效、生活质量明显好于对照组,中位生存期高于对照组,甲胎蛋白和不良反应发生率低于对照组,组间对比差异具有统计学意义(P<0.05)。结论:参芪扶正注射液与TACE联合治疗肝癌可以起到增加疗效、减少副作用的效果,提高患者的生活质量,延长生存期限。
Objective: To observe the clinical efficacy and adverse reactions of Shenqi Fuzheng injection combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods: A total of 94 patients with hepatocellular carcinoma who were admitted to Hebei General Administration of Civil Hospital from November 2013 to May 2015 were randomly divided into treatment group (n = 51) and control group (n = 43). All of them were treated with transcatheter arterial chemoembolization. Fuzheng injection, observed the survival time of two groups, biochemical changes, adverse reactions, clinical efficacy and quality of life improvement. Results: The total effective rate was 76.47% in the treatment group, which was 67.44% higher than that in the control group. The clinical curative effect and quality of life in the treatment group were significantly better than those in the control group. The median survival time was higher than that in the control group. The incidence of alpha-fetoprotein and adverse reactions In the control group, the difference between the groups was statistically significant (P <0.05). Conclusion: The combination of Shenqi Fuzheng Injection and TACE in the treatment of liver cancer can increase the curative effect, reduce the effect of side effects, improve the quality of life of patients and prolong the survival period.